Book some profits in Vimta Labs: Avinnash Gorakssakar

Avinnash Gorakssakar, Market Expert told CNBC-TV18, "Vimta Labs is a leading contract research laboratory player and I think looking at the kind of traction in this business, our sense is that typically FY18 should also be a good year. The company has a very large pharmaceutical kind of portfolio and I think definitely FY18 also should be better but my sense would be that since the stock has doubled in the last one year, at least some part of the profit should be taken out of the table. I think the rest could be held on but definitely longer term prospects look good."

The share touched its 52-week high Rs 164.40 and 52-week low Rs 81.20 on 13 July, 2017 and 13 July, 2016, respectively.